AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04395248 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparing the effectiveness of preoxygenation between high-flow nasal cannula and facemask
Description: In the HFNC group, preoxygenation will be performed using HFNC (Optiflow™, Fisher \& Paykel Healthcare, Auckland, NZ), nasal prongs set at 30 L/min flow of heated and humidified 100% oxygen. In the facemask group, patients will breath spontaneously with an anesthetic facemask and 100% oxygen 15 L/min. Gas flow for HFNC or facemask can be adjusted depending on patients' tolerance. During laryngoscopy intubation, HFNC will be left in place with the nasal flow escalated to 50 L/min of 100% oxygen in order to achieve apneic oxygenation. In the facemask group, the facemask will be removed when apnea occurs. After tracheal intubation, correct placement of the endotracheal tube will be confirmed by capnography and the nasal prongs of the HFNC group will be removed.
Study NCT04395248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Type of volatile anesthetics and M-Entropy guidance of anesthesia depth
Description: At the operating room, a M-Entropy™ sensor and S/5™ module (GE Healthcare, Helsinki, Finland) will be applied to all patients' forehead before induction of anesthesia according to the manufacturer's recommendations. Patients will be randomized to Sevoflurane or Desflurane as the single volatile anesthetics for general anesthesia.~Besides, patients will be randomized to M-Entropy group or controls. In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the Response and State Entropy value between 40 and 60 from the start of anesthesia to the end of surgery. In the usual care group, dosage of volatile anesthetics will be titrated according to clinical judgment. M-Entropy monitoring will be continued in the usual care group, but the Entropy number and EEG waveform will be concealed from the anesthetist in charge.
Study NCT01337726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Psychotherapy and Illness Management
Description: Participants will have 10 weekly visits with a study clinician at their home and by phone. They will focus on their self care and illness management as well as how to manage their mood/cope emotionally. Follow up assessments will occur at 26 and 52 weeks.
Study NCT01337726 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Illness Management Only
Description: Participants in this group will have 10 weekly sessions with a study clinician at home and by phone. They will focus only on how they manage their illness. Follow up assessments will occur at 26 and 52 weeks.
Study NCT02387567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Paraspinal block with 3ml lidocaine injection at 1%.
Study NCT02387567 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Lidocaine
Description: Sham injection, without lidocaine.
Study NCT02387567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Standard treatment only, without lidocaine or sham injection.
Study NCT02387567 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment only, without lidocaine or sham injection.
Study NCT02387567 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment only, without lidocaine or sham injection.
Study NCT01604369 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medtronic Freezor Max Cardiac Cryoablation Catheter
Description: Cryoablation is performed using a sequential application technique point-by-point from the tricuspid annulus to the inferior vena cava. Ablation is performed at a target temperature of -80 ºC. Each application will last for 240 seconds.
Study NCT04272489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG-Pattern Recognition Controller
Description: Using an electromyographic (EMG)-based pattern recognition controller to move an upper limb prosthetic device in a home trial.
Study NCT04272489 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMG-Pattern Recognition Controller
Description: Using an electromyographic (EMG)-based pattern recognition controller to move an upper limb prosthetic device in a home trial.
Study NCT04299217 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zynamite®
Description: Zynamite® is a novel mango (Mangifera indica) leaf extract standardized to contain 60% of the polyphenol mangiferin. Zynamite® is classified as a food or food supplement and is available for purchase within the EU. Zynamite® is not associated with any significant deleterious side effects.
Study NCT04299217 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator (carrier)
Study NCT01405469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peroral Endoscopic Myotomy
Description: A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. An electric generator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips
Study NCT02951936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NiCAS treated
Description: Measure each patient with the NiCAS once a day If Cardiac Index \< 2.9 +Total Peripheral resistance Index >3000+Mean arterial pressure >70mmHG then add vasodilators.~If Heart Rate\<60 consider to reduce beta blockers dose If Cardiac Index>4.2 and Mean arterial pressure 70-100mmHG and HR >100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics
Study NCT02951936 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non NiCAS treated
Description: Measure each patient with the NiCAS once a day Do note use the NiCAS parameters to direct treatment For treatment we will use the standard care
Study NCT04751045 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS liver biopsy
Description: Endoscopic ultrasound guided liver biopsy
Study NCT00730002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: diffusion Imaging
Description: MRA of the Brain
Study NCT00730002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perfusion imaging.
Description: MRA of the brain
Study NCT02033096 — intervention group
Intervention type: DRUG
Intervention: Stannsoporfin
Description: No intervention was administered during this observational study
Study NCT02033096 — intervention group
Intervention type: DRUG
Intervention: Placebo Control
Description: No intervention was administered during this observational study
Study NCT02033096 — intervention group
Intervention type: OTHER
Intervention: Phototherapy (as needed)
Description: No intervention was administered during this observational study
Study NCT02225106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Subjects will be treated with oral methylphenidate, using a forced titration up to a dose of 30 mg given twice daily for 4 weeks. At that point, the neuropsychologic tests are repeated.
Study NCT01767727 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Soft tissue coverage
Description: The dorsal homodigital island flaps are used for soft tissue coverage of multiple finger defects
Study NCT04034355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calmangafodipir (5 µmol/kg)
Description: PledOx will be given to patients as an i.v. infusion, on top of mFOLFOX6 chemotherapy. PledOx is a solution in 20 mL single dose glass vials.
Study NCT04034355 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via the same route as PledOx (i.v. infusion). Placebo is a solution in 20 mL single dose glass vials.
Study NCT01956708 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: RIPC
Description: 3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion
Study NCT01956708 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RIPC
Description: 3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion
Study NCT02914769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ayahuasca
Description: patients will receive a single dose of ayahuasca.
Study NCT02914769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients will receive a single dose of a passive placebo.
Study NCT01709812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individualized patient support program
Description: individualized patient support with compliance supporting tools
Study NCT01709812 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Study NCT04154358 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV testing
Description: will perform HPV testing with self-collected specimen
Study NCT04458961 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-stage
Description: A one-stage revision operation involves one operation to remove the joint, thoroughly cleaning the infected area and then implanting a new joint immediately.
Study NCT04142788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer
Description: Patiromer (8.4g/day to 25.2g/day) and spironolactone (up to 200mg/day) or eplerenone (up to 50mg/day if spironolactone not acceptable). Treatments should be titrated to maintain serum potassium close to the target of 4.5mmol/L.
Study NCT01225939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8329
Description: tablet
Study NCT04458961 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-stage
Description: A two-stage revision operation involves two operations: the joint is removed in one operation, a temporary spacer device is inserted, then the infection is treated with antibiotics, and then a new joint is implanted in a second operation.
Study NCT02061176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal Haemorrhoidal Dearterialization
Study NCT02061176 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Haemorrhoidectomy
Study NCT00270387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natrecor (nesiritide)
Study NCT01365455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab 150 mg
Description: secukinumab (AIN457) 150mg or 300mg subcutaneous
Study NCT01365455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to secukinumab 150 mg
Description: Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous
Study NCT01365455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to secukinumab 150 mg
Description: Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous
Study NCT01920243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Mechanics Program
Description: The intervention will consist of six modules that will address attitudes, self-monitoring, communication and organizational skills, problem solving skills and stress management as presented through the Health Mechanics program. These modules are designed to take place over 6 phone calls of approximately 45 minutes each. In order to provide flexibility for the participants, the quantity and duration of calls may vary depending on the extent that the participant completes the homework and the amount of time they need to learn the skill.
Study NCT00916448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Description: capsules of 150 mg, 2 capsules, twice daily on 4 consecutive days
Study NCT00916448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E. coli endotoxin
Description: 2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
Study NCT00916448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: E. coli endotoxin
Description: 2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
Study NCT03117946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological samples
Description: blood and tumor tissue sample
Study NCT02843191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: 5-FU, Leucovorin, and Oxaliplatin (FOLFOX regimen)
Study NCT02843191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: 5-FU, Leucovorin, and Oxaliplatin (FOLFOX regimen)
Study NCT00483366 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: capecitabine
Description: Dose level Capecitabine~-1 400 mg/m2 bid~0 500 mg/m2 bid~1. 500 mg/m2 bid~2. 600 mg/m2 bid~3. 600 mg/m2 bid~4. 725 mg/m2 bid~5. 725 mg/m2 bid~6. 850 mg/m2 bid~7. 850 mg/m2 bid
Study NCT00483366 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: gemcitabine hydrochloride
Description: Dose level Gemcitabine~-1 400 mg/m2 0 450 mg/m2~1. 550 mg/m2~2. 550 mg/m2~3. 675 mg/m2~4. 675 mg/m2~5. 825 mg/m2~6. 825 mg/m2~7. 1000 mg/m2
Study NCT00483366 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: imatinib mesylate
Description: Dose level Imatinib~-1 400 mg/d 0 400 mg/d~1. 400 mg/d~2. 400 mg/d~3. 400 mg/d~4. 400 mg/d~5. 400 mg/d~6. 400 mg/d~7. 400 mg/d
Study NCT00483366 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: mutation analysis
Description: C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
Study NCT00483366 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: nucleic acid sequencing
Description: C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
Study NCT00483366 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: polymerase chain reaction
Description: C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
Study NCT01225939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8329
Description: Solution
Study NCT04117451 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Propolis
Description: Investigating the impact of propolis mouthwash on oral and cardiovascular health
Study NCT04117451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propolis
Description: Investigating the impact of propolis mouthwash on oral and cardiovascular health
Study NCT01272648 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: RePCa A
Description: Intervention patients receives two consultations with a specialist oncology nurse three and six month after ended radiotherapy. The focus are on what is important for the patients at the specific time. The patient can bring his spouse.~Furthermore the patients have two physiotherapy consultations with guidance in pelvic floor exercises and an individual home-program of pelvic and functional training exercises
Study NCT01272648 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RePCa A
Description: Intervention patients receives two consultations with a specialist oncology nurse three and six month after ended radiotherapy. The focus are on what is important for the patients at the specific time. The patient can bring his spouse.~Furthermore the patients have two physiotherapy consultations with guidance in pelvic floor exercises and an individual home-program of pelvic and functional training exercises
Study NCT03313206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Neo-adjuvant therapy :~* Anti-PD1 antibody will be used (pembrolizumab, Merck®) intravenously at a dose of 200 mg every 3 weeks. The patient will receive 4 injections maximum over 12 weeks. According to the investigator's opinion, the 4th injection might be cancelled in order to perform surgery from week 10 and not after week 13.~* Tumor response will be assessed 2 weeks after the last injection both clinically and radiologically (by CT-scan and MRI).~Maintenance therapy by anti-PD1 antibody (pembrolizumab, Merck®) will be then used intravenously at a dose of 200 mg every 3 weeks for a maximum period of one year, starting one month after the end of radiotherapy.
Study NCT03313206 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery will be performed (endoscopically if possible) 3 weeks after the last injection, at the earliest week 10 and at the latest at week 13 and will be completed by radiotherapy using IMRT technology according to the International and European Rhinologic Societies guidelines.
Study NCT03313206 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Surgery will be performed (endoscopically if possible) 3 weeks after the last injection, at the earliest week 10 and at the latest at week 13 and will be completed by radiotherapy using IMRT technology according to the International and European Rhinologic Societies guidelines.
Study NCT03313206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: up to 26 evaluable patients will be treated with pembrolizumab combined with orally lenvatinib at a daily dose of 20 mg for 6 weeks started on the day of the first anti-PD1 dose.
Study NCT02749045 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: SPECT imaging
Description: myocardial perfusion imaging
Study NCT00768664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: 45 mg by continuous oral dosing
Study NCT04038957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: SEP-363856 50mg, 75mg flexable dosing, dosed once daily capsule
Study NCT01698593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5%
Study NCT01698593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5% + Epinephrine (1:200,000)
Study NCT01794754 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Care as usual
Study NCT01794754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Description: Occupational therapy in the waiting period before surgery. Occupational therapy comprises orthoses for the CMC-joint, hand exercises, and use of alternative working methods and assistive devices. The participants are encouraged to perform hand exercises three times a week for the first 12 weeks, and to use orthosis as much as possible, both during daytime (day orthosis) and night time (night orthosis).
Study NCT00610324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: Twice-daily oropharyngeal cleansing with 0.2% Chlorhexidine gluconate
Study NCT00610324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium permanganate
Description: Twice-daily oropharyngeal cleansing with 0.01% Potassium permanganate
Study NCT01730040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
Study NCT01908634 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk-based Strawberry Beverage without meal
Study NCT01908634 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water-Based Strawberry Beverage without meal
Study NCT01908634 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk-based strawberry Beverage with meal
Study NCT01908634 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water-Based strawberry Beverage with meal
Study NCT02128789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elder Tree website
Description: Elder Tree is a private, secure information, support and communication website developed for this study.
Study NCT01072357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin® (bevacizumab)
Description: One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
Study NCT01072357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl & Refresh Liquigel
Description: One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks
Study NCT01730040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin over-encapsulated tablets orally.
Study NCT01730040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin over-encapsulated tablets orally.
Study NCT02615912 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5%